PHARMACY

Bush vetoes SCHIP bill for second time

BY Drew Buono

WASHINGTON President Bush vetoed a bill yesterday that would have continued the State Children’s Health Insurance Program for another five years, according to the washingtonpost.com.

Pushed by the Democratic-led Congress but also supported by many Republicans, the bill was aimed at providing health insurance to about 10 million children in low- and moderate-income families. Taxes on cigarettes and other tobacco products would have been increased to pay for the aid.

Bush vetoed a version of the bill in October but Congress quickly passed another one that included some changes but not enough to satisfy the White House.

“Because the Congress has chosen to send me an essentially identical bill that has the same problems as the flawed bill I previously vetoed, I must veto this legislation too,” Bush wrote in a message to the House of Representatives.

“This is indeed a sad action for him to take, because so many children in our country need access to quality health care,” House Speaker Nancy Pelosi, a California Democrat, told reporters.

Democratic leaders said they plan a temporary funding bill to ensure that those children keep their coverage through the fiscal year ending Sept. 30.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

FDA grants Mylan tentative approval for generic Lamictal

BY Drew Buono

PITTSBURGH, Pa. Mylan Pharmaceuticals has received tentative approval from the Food and Drug Administration for a generic version of Lamictal.

Lamictal, by GlaxoSmithKline is used to treat epilepsy and bipolar I disorder. The generic version, lamotrigine, will be available in 25 mg, 100 mg, 150 mg and 200 mg tablet strengths.

The drug had sales of about $1.97 billion for the 12 months ended Sept. 30, 2007.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

NoMoreClipboard.com, ReliefInsite.com partner to offer online pain management module

BY Drew Buono

FORT WAYNE, Ind. NoMoreClipboard.com and ReliefInsite.com have teamed up to ease pain management for patients, practitioners and caregivers. The two have incorporated a free pain management module into the NoMoreClipBoard.com interface.

NoMoreClipboard.com, an online personal health record company, works with health care providers and industry groups to simplify transactions between patients, providers and payors, saving each party significant time and effort. Within NoMoreClipboard.com, patients or caregivers can store information such as allergies, medications and medical conditions in a secure environment. The patient can then choose to share their records with selected health care providers, and NoMoreClipboard.com takes care of securely transferring the record to physicians on behalf of the patient. ReliefInsite.com is a health care information technology company that provides secure online pain management services.

The ReliefInsite.com pain management module within NoMoreClipboard.com allows patients to share their daily pain diary with doctors, nurses, therapists, family members and friends. In addition, ReliefInsite.com offers dynamic, real-time graphical reports to help improve patient compliance, and assists case managers by monitoring therapy effectiveness with time-stamped records, revealing the interaction between pain levels and the patient’s personal and professional lifestyle.

“NoMoreClipboard.com allows patients to store and manage health information and share it with their health care providers, easily and seamlessly,” said Jeff Donnell, NoMoreClipboard.com vice president of marketing. “The ReliefInsite pain management module makes our personal health record even more valuable for the 50 million Americans who currently suffer from chronic pain.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?